Benoit Laplaize of Lesaffre Human Care-France to Speak at SupplySide West
October 1, 2010
Benoit Laplaize, global sales and marketing manager for Lesaffre Human Care based in Lille, France, will introduce the company's new probiotic yeast, Lynside® Pro GI+ and results from the company's 200-person clinical trial at the SupplySide West VendorWorks on Thursday, October 21 from 2:30-3:20 p.m. at the show-floor presentation area, #10068.
"There are only a few clinical studies on the efficacy of probiotics in relieving IBS symptoms and those studies were conducted with a small number of subjects," said Laplaize. "The results of those studies lack consistency and statistical significance."
Lesaffre's 200 IBS-patient study showed that consuming 500mg of Lynside® Pro GI+ per day is well-tolerated and reduces abdominal pain or discomfort after taking Pro GI+ for four weeks," Laplaize said.
"IBS affects about 20% of the American population," said Laplaize. "It is a relapsing functional intestinal disorder commonly characterized by abdominal pain or discomfort, bloating, distension, and disordered defecation such as diarrhea and/or constipation. The use of probiotics is a common practice for IBS care."
For more than 150 years, Lesaffre has been the world leader in manufacturing premium quality yeast and yeast derivatives. The U.S. Human Care division focuses exclusively on marketing yeast products that advance human health by nature of their overall nutritional value or condition-specific health benefits. For manufacturers, Lesaffre offers a variety of yeast ingredients under the LYNSIDE® brand for use in functional foods, dietary supplements, cosmetics and clinical nutrition.